The research of VCE-003.2 on Huntington's Disease has been published in Scientific Reports
Posted on November 29, 2016
Córdoba, Spain – July 19th, 2016 – The high potential of VCE-003.2 for the treatment of Huntington's Disease (HD) and other neurodegenerative diseases with neuroinflammatory traits has been described in the paper published in the last number of the Scientific Reports journal. The work has been coordinated by researches of Maimonides Biomedical Research Institute at Córdoba (IMIBIC, Spain) and VivaCell, in collaboration with the Institute Ramón y Cajal of Health Research (IRYCIS, Madrid, Spain), the University Complutense of Madrid (Spain), the Network of Research in Neurodegenerative Diseases (CIBERNED, Madrid, Spain), and the University of the Piamonte Orientale (Italy).
Cannabinoids have shown to exert neuroprotective actions in animal models by acting at different targets including canonical cannabinoid receptors and PPARγ. We previously showed that VCE-003, a cannabigerol (CBG) quinone derivative, is a novel neuroprotective and anti-inflammatory cannabinoid acting through PPARγ. We have now generated a non-thiophilic VCE-003 derivative named VCE-003.2 that preserves the ability to activate PPARγ and analyzed its neuroprotective activity. This compound exerted a prosurvival action in progenitor cells during neuronal differentiation, which was prevented by a PPARγ antagonist, without affecting neural progenitor cell proliferation. In addition, VCE-003.2 attenuated quinolinic acid (QA)-induced cell death and caspase-3 activation and also reduced mutant huntingtin aggregates in striatal cells. The neuroprotective profile of VCE-003.2 was analyzed using in vivo models of striatal neurodegeneration induced by QA and 3-nitropropionic acid (3NP) administration. VCE-003.2 prevented medium spiny DARPP32(+) neuronal loss in these Huntington's-like disease mice models improving motor deficits, reactive astrogliosis and microglial activation. In the 3NP model VCE-003.2 inhibited the upregulation of proinflammatory markers and improved antioxidant defenses in the brain. These data lead us to consider VCE-003.2 to have high potential for the treatment of Huntington's disease (HD) and other neurodegenerative diseases with neuroinflammatory traits.
VIvacell Biotechnology España SL